Please Wait
Applying Filters...
menu
    • menu
    Excipient Market Overview: Evonik launches high-purity excipients; India mandates disclosures from March 2026

    Data Compilation
    #PharmaFlow

    Pipeline Prospector October 2025: Novartis to buy Avidity for US$ 12 bn; FDA approves Bayer’s med to treat hot flashes

    Stock Recap
    #PipelineProspector

    Menu

    Rifaximin

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    INTERMEDIATES

    FINISHED DOSAGE FORMULATIONS

    DRUG PRODUCT COMPOSITIONS

    RELATED EXCIPIENT COMPANIES

    EXCIPIENTS BY APPLICATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    MARKET PLACE

    PATENTS & EXCLUSIVITIES

    REF. STANDARDS & IMPURITIES

    PharmaCompass
    $ API Ref.Price (USD/KG) : 234Xls download

    Filters

    clear-filterReset all filters
    ListList of Suppliers
    refreshReset Filter
    refresh Reset Filter
    Price Info Price Info
    product-page Product Main Page

    Log in to download the data

    Last Updated on PharmaCompass Virtual Booth Country Certificate Holder Certificate No. Substance Issue Date Status Type End Date Substance No.
    31/10/2025 Granules India Limited
    India
    		 GRANULES INDIA LIMITED Hyderabad IN CEP 2012-146 - Rev 02 Rifaximin 2024-06-10 Valid Chemical 2362
    31/10/2025 Cosma (C.F.M. Group)
    Italy
    		 Cosma S.p.A. Ciserano IT CEP 2022-368 - Rev 00 Rifaximin 2024-09-02 Valid Chemical 2362